| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1025416595 |
| P356 | DOI | 10.1007/S10096-011-1188-Z |
| P698 | PubMed publication ID | 21311938 |
| P50 | author | Peter J Coote | Q57968234 |
| Andrew P. Desbois | Q43226446 | ||
| P2860 | cites work | Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. | Q46034505 |
| Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin | Q46173172 | ||
| The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. | Q46415786 | ||
| New effective sources of the Staphylococcus simulans lysostaphin | Q46432260 | ||
| Cytoplasmic expression of mature glycylglycine endopeptidase lysostaphin with an amino terminal hexa-histidine in a soluble and catalytically active form in Escherichia coli | Q46718693 | ||
| In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus. | Q54228026 | ||
| Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin. | Q54446084 | ||
| Conformational and functional studies of gomesin analogues by CD, EPR and fluorescence spectroscopies. | Q54454194 | ||
| Experimental evolution of resistance to an antimicrobial peptide. | Q54949785 | ||
| The selective activity of lysostaphin in vivo | Q69993410 | ||
| Peptide antibiotics | Q73073957 | ||
| In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus | Q79399842 | ||
| Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model | Q81234087 | ||
| Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: the case of lysostaphin | Q24815954 | ||
| LYSOSTAPHIN: A NEW BACTERIOLYTIC AGENT FOR THE STAPHYLOCOCCUS | Q28156580 | ||
| Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis | Q28379547 | ||
| Antistaphylococcal nanocomposite films based on enzyme-nanotube conjugates | Q28749815 | ||
| Mechanisms of antimicrobial peptide action and resistance | Q34181099 | ||
| Staphylococcus aureus mutants with increased lysostaphin resistance | Q35075303 | ||
| Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test | Q35126210 | ||
| Antibacterial peptides for therapeutic use: obstacles and realistic outlook | Q36556909 | ||
| Detergent-like actions of linear amphipathic cationic antimicrobial peptides | Q36575037 | ||
| Lantibiotics: peptides of diverse structure and function. | Q36824144 | ||
| Direct observation of Staphylococcus aureus cell wall digestion by lysostaphin | Q36994350 | ||
| Lysostaphin: an antistaphylococcal agent | Q37209589 | ||
| Structure, membrane orientation, mechanism, and function of pexiganan--a highly potent antimicrobial peptide designed from magainin. | Q37325942 | ||
| Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery | Q37762644 | ||
| Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus | Q39477127 | ||
| Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis | Q39651918 | ||
| High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme | Q39856762 | ||
| cDNA and protein sequence of bovine lactoferrin | Q40527250 | ||
| In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections | Q43141290 | ||
| Surface disinfection properties of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, against methicillin-resistant Staphylococcus aureus (MRSA). | Q43285540 | ||
| Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate | Q43778948 | ||
| Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin | Q44110332 | ||
| P433 | issue | 8 | |
| P921 | main subject | antimicrobial peptide | Q1201508 |
| P304 | page(s) | 1015-1021 | |
| P577 | publication date | 2011-02-11 | |
| P1433 | published in | European Journal of Clinical Microbiology & Infectious Diseases | Q15754378 |
| P1476 | title | Bactericidal synergy of lysostaphin in combination with antimicrobial peptides | |
| P478 | volume | 30 |
| Q50962785 | A central composite rotatable design (CCRD) approach to study the combined effect of antimicrobial agents against bacterial pathogens. |
| Q92437192 | Antimicrobial activity of bacteriophage derived triple fusion protein against Staphylococcus aureus |
| Q49631381 | Combination Strategies to Enhance the Efficacy of Antimicrobial Peptides against Bacterial Biofilms |
| Q42008907 | Enhanced efficacy of synergistic combinations of antimicrobial peptides with caspofungin versus Candida albicans in insect and murine models of systemic infection |
| Q92508905 | Fusion of Lysostaphin to an Albumin Binding Domain Prolongs Its Half-Life and Bactericidal Activity in the Systemic Circulation |
| Q47096972 | In vitro activity of recombinant lysostaphin in combination with linezolid, vancomycin and oxacillin against methicillin-resistant Staphylococcus aureus |
| Q39159902 | Lactoferrin: Balancing Ups and Downs of Inflammation Due to Microbial Infections |
| Q37973268 | Microbial and fungal protease inhibitors--current and potential applications |
| Q38053102 | Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus |
| Q92068266 | Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37 |
| Q37722952 | Synergistic effects of antimicrobial peptide DP7 combined with antibiotics against multidrug-resistant bacteria |
Search more.